Chinanews.com, Beijing, June 20 (Reporter Li Yanan) 2020 China Anti-Cancer Association Brain Glioma Professional Committee GBM Summit Forum was held online on the 20th. Aipun, the first tumor electric field treatment, announced here that it will be officially listed in mainland China. In combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) patients, and as a monotherapy for the treatment of patients with recurrent glioblastoma. At the meeting, the country's first glioma patient care platform, "Shou Nu", was launched to help glioma patients obtain professional treatment and rehabilitation guidance.
The deputy director of the Beijing Neurosurgery Research Institute, the initiator and founder of the China Glioma Genome Atlas database, and Professor Jiang Tao, Beijing Tiantan Hospital: "In China, more than 45,000 patients are diagnosed with glioblastoma every year , Traditional surgery and radiotherapy and chemotherapy have a limited effect on improving the overall survival of patients, and there has been a lack of innovative treatments for a long time. As the first innovative therapy for glioblastoma marketed in the mainland of China in 15 years, the tumor electric field treatment is not only It brings new hope to Chinese patients with glioblastoma, is expected to prolong their lives, and it also opens up new ideas for the treatment of domestic gliomas."
Glioblastoma is the most common and invasive adult brain tumor, with the highest mortality rate except for pancreatic cancer. As the most common malignant tumor of the nervous system, glioblastoma disease progresses very quickly and is prone to relapse. The recurrence rate of patients is as high as 100%, and the five-year survival rate is less than 5%. It is considered to be the most difficult in neurosurgical treatment One of refractory tumors.
Tuple electric field treatment Aipun acts on the tubulin of proliferating cancer cells through low-intensity, medium-frequency AC electric fields, interfering with tumor cell mitosis, inhibiting tumor growth and causing cancer cells affected by the electric field to die. International Phase III multi-center clinical study EF-14 confirmed that among newly diagnosed GBM patients, the five-year overall survival rate of patients who received tumor electric field treatment with combination of aipudan and temozolomide was more than doubled compared with temozolomide alone. From 5% to 13%, the median overall survival time was extended from 16 months to 20.9 months. In the 2018 NCCN guidelines, "conventional radiotherapy + simultaneous and adjuvant TMZ chemotherapy + electric field treatment" is recommended as glioblastoma type 1. The first "Guideline for the Diagnosis and Treatment of Glioma (2018)" by the National Health and Safety Commission of China also specifically recommends the use of tumor electric field treatment for newly developed glioblastoma and recurrent high-grade glioma.
Professor Mao Ying, the chairman-elect of the Chinese Medical Association Neurosurgery Branch and the executive deputy director of neurosurgery at Huashan Hospital Affiliated to Fudan University, said: "Different from traditional therapies such as surgery, drugs and radiotherapy, in addition to the obvious advantages in terms of efficacy, tumors Electric field treatment is more convenient and non-invasive, which will help patients return to daily life. Hope that more domestic glioblastoma patients will benefit from it in the future and help further improve the overall treatment level of gliomas in China."
Up to now, tumor electric field treatment has treated more than 15,000 glioblastoma patients worldwide. Several global phase III key clinical studies on tumor electric field treatment are also being carried out to evaluate their efficacy in brain metastasis, non-small cell lung cancer, pancreatic cancer and ovarian cancer, and phase II clinical studies on liver cancer and gastric cancer are also ongoing in.
According to reports, in order to provide more comprehensive, authoritative and practical disease science and rehabilitation knowledge to patients with gliomas, the first comprehensive patient care charity project for glioma patients in the country-"First Care" was officially launched on the day start up. The project was initiated by the Beijing Aipu Cancer Patient Care Foundation and national authoritative hospitals and experts in the field of gliomas. It aims to provide online forms of expert lectures and provide various forms of expert disease science and doctor-patient interaction to answer questions Confusion, help patients with glioma to obtain professional treatment and rehabilitation guidance, assist patients with standardized treatment and improve quality of life. (Finish)